Compass Therapeutics, Inc. — Director's Dealing 2020

Dec 23, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Compass Therapeutics, Inc. (CMPX)
CIK: 0001738021
Period of Report: 2020-12-22

Reporting Person: Schuetz Thomas J. (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-22	Stock Option (Right to Buy)	$5.00	A	250000	Acquired	2030-12-22	Common Stock (250000)	Direct

Footnotes

F1: 50% of this option is immediately vested and exercisable, with the remainder vesting in 24 substantially equal monthly installments thereafter.